SPECIAL OFFER
Tuesday 7 November 2017 | | | If you attended the Master Investor Show in March and heard Jim Mellon speaking about his upcoming book on the investment potential in the longevity field, then you will be pleased to know Juvenescence: Investing in the Age of Longevity is now available.
To celebrate, we have an exclusive offer for you. By using the code MASTERINVESTOR at the checkout, you can get £3 off the RRP of £16.99 for orders to be delivered within the UK.
What is Juvenescence?
In Juvenescence, Jim Mellon and Al Chalabi describe the diseases of ageing and the current and soon to be marketed treatments that will enable everyone to live much longer. The book is necessarily quite science heavy, as it has to convey the differing opinions and strands of research. They have travelled extensively in the US and Europe speaking to the key opinion leaders and visiting laboratories and companies working in the field of life extension. They have written this up for the investor, stripping away as much of the technical jargon as possible and demystifying the information to help readers understand the science.
As technology and biology fuse into greater capabilities, new techniques (such as gene therapy and genetic engineering) will become routine. Deep learning strategies to develop personalised drugs to accelerate the development of drug therapies will sit alongside genetic screening and transform medicine. Jim and Al forecast that the average life expectancy in the developed world will rise to 110-120 within 20 years and thereafter, much higher. The old life paradigm of born, learn, earn, retire and expire is about to be radically changed. The entirety of our lives will be upended; we will earn continuously, we will start families later, we will enjoy multiple careers and we will have more time for leisure and self-development.
Why should you read the book?
With their previous books published over the past decade the authors, Jim and Al Chalabi have established an excellent track record of recognising investment opportunities before they become mainstream, starting with forecasting the Great Recession in 2008. This new book summarises their year-long research into longevity and the most exciting opportunities for investors to capitalise on.
If we are all going to live much longer lives, how are we going to be able to afford it? Jim and Al have identified exciting investment opportunities and companies that will hopefully provide readers with ultra-long-lived portfolios alongside their ultra-long lives.
| | | "Jim Mellon and Al Chalabi have once again written the gold standard guide to investing in a key emerging area of technology."
David A. Sinclair, Ph.D., Professor of Genetics, Harvard Medical School. | | | | WANT TO FIND OUT MORE? READ THE OCTOBER ISSUE OF MASTER INVESTOR MAGAZINE! | | |
Juvenescence - Investing in an age of longevity - Aubrey de Grey - Controversial scientist reveals all in this exclusive interview
- 9 funds to retire on - We name our top funds for income drawdown
- High-yield stocks - Are there any bargains to be uncovered?
- Commercial property - The way forward for UK property investors?
| | | |
Ingen kommentarer:
Send en kommentar